Metabolic side effects of atypical antipsychotics in early onset schizophrenia: One year follow-up pilot study

2008 ◽  
Vol 23 ◽  
pp. S159
Author(s):  
J.L. Goeb ◽  
S. Marco ◽  
A. Duhamel ◽  
R. Jardri ◽  
G. Kechid ◽  
...  
Keyword(s):  
Pilot Study ◽  
Side Effects ◽  
Early Onset ◽  
Atypical Antipsychotics ◽  
Early Onset Schizophrenia ◽  
Metabolic Side Effects ◽  
One Year

Expressed emotion and early onset schizophrenia: a one year follow-up

1991 ◽  
Vol 21 (3) ◽  
pp. 675-685 ◽  
Author(s):  
John Stirling ◽  
Digby Tantam ◽  
Philip Thomas ◽  
David Newby ◽  
Linda Montague ◽  
...  
Keyword(s):  
Early Onset ◽  
Expressed Emotion ◽  
Acute Onset ◽  
Work Study ◽  
Early Onset Schizophrenia ◽  
Early Admission ◽  
Elapsed Time ◽  
One Year ◽  
The Relationship

SYNOPSISKey relatives of 33 first or early admission psychotic patients (mainly schizophrenics) were interviewed to determine household levels of expressed emotion (EE). The patients were followed up for 12 months from index admission, during which time 13 (39%) experienced psychotic relapse. There was no association between relapse rate and household EE, but correlations between individual components of EE and pre-morbid measures suggest that level of criticism may be related to less acute onset of index episode, greater elapsed time since first signs of illness, and poor adjustment in the realm of work/study. The results are discussed in the context of continuing uncertainties about the precise nature of the relationship between EE and relapse.

Use of atypical antipsychotics in early onset schizophrenia

2011 ◽  
Vol 26 (S2) ◽  
pp. 324-324
Author(s):  
M. Marin Mayor ◽  
N. Martinez Martin ◽  
E. Verdura Vizcaino ◽  
R.A. Codesal Julian
Keyword(s):  
Side Effects ◽  
Children And Adolescents ◽  
Early Onset ◽  
Atypical Antipsychotics ◽  
Metabolic Effects ◽  
Psychotic Symptoms ◽  
Antipsychotic Treatment ◽  
Childhood And Adolescence ◽  
Early Onset Schizophrenia ◽  
Children And Adolescent

IntroductionChildhood or Early Onset Schizophrenia (EOS), defined as the onset of psychotic symptoms before the thirteenth birthday, represents a rare, clinically severe variant, associated with significant chronic functional impairment and poor response to antipsychotic treatment. Despite of that, in clinical practice, atypical agents have become the treatment of choice in patients with EOS.AimsTo review the different pharmacological strategies, in which an atypical antipsychotic was used in the management of EOS in childhood and adolescence.MethodsWe conducted a literature search of articles related to the use of atypical antipsychotics in children and adolescents with EOS in the last 20 years from the Medline database.ResultsSeveral atypical antipsychotics, such as Risperidone, Olanzapine, Quetiapine, Aripiprazol and Clozapine were consistently found to reduce the severity of psychotic symptoms in EOS when compared to placebo. Although Clozapine has demonstrated to be more efficacious than other atypical and typical antipsychotics, it remains the medication of last resort due to its profile of side effects. Finally, in general, children and adolescent have a higher risk of extrapyramidal symptoms, akathisia, prolactin elevation, sedation and metabolic effects of atypical antipsychotics than adults.ConclusionsAntipsychotics are the mainstay of treatment of EOS. Randomized controlled trials suggest a trend to superior efficacy for atypical antipsychotics over classic antipsychotic. Children and adolescents trend to be more sensible to antipsychotic side effects. Clinicians should be aware of this problem and be careful when monitoring this type of treatment.

scholarly journals Metabolic Side Effects of Risperidone in Children and Adolescents With Early-Onset Schizophrenia

2008 ◽  
Vol 10 (06) ◽  
pp. 486-487 ◽  
Author(s):  
Jean-Louis Goeb ◽  
Sophie Marco ◽  
Alain Duhmael ◽  
Renaud Jardri ◽  
Geraldine Kechid ◽  
...  
Keyword(s):  
Side Effects ◽  
Children And Adolescents ◽  
Early Onset ◽  
Early Onset Schizophrenia ◽  
Metabolic Side Effects

scholarly journals A comparative study of metabolic side effects of risperidone and olanzapine in the treatment of schizophrenia

2019 ◽  
Vol 8 (11) ◽  
pp. 2561
Author(s):  
Lavanya Nagaraj ◽  
Naveen Kumar Madalageri
Keyword(s):  
Side Effects ◽  
Comparative Study ◽  
Atypical Antipsychotics ◽  
Tertiary Care ◽  
Care Hospital ◽  
Metabolic Side Effects ◽  
Schizophrenic Patients ◽  
Group 2 ◽  
One Year ◽  
Typical Antipsychotics

ABSTRACTBackground: Schizophrenia is one of most serious chronic psychiatric disorder, which affects about 1% of population. Treatment of schizophrenia comprises of typical antipsychotics and or atypical antipsychotics. Typical antipsychotics like haloperidol have extrapyramidal side effects which limit their use in chronic cases. Atypical antipsychotics though have better treatment response, they have metabolic side effects like hypercholesteremia, hypertriglyceridemia and hyperglycaemia. As there is paucity of data in Indian population the present study has been taken up to compare the metabolic side effects of risperidone and olanzapine in the treatment of schizophrenic patients in a tertiary care hospital.Methods: It was a comparative study conducted on 60 patients of Schizophrenia for one year in a tertiary care hospital. The study subjects were randomly assigned into 2 groups of 30 patients each, where group 1 were treated with atypical antipsychotic drug risperidone and group 2 with Olanzapine and both groups received the treatment for one year. Metabolic side effects like hypercholesteremia, hypertriglyceridemia and hyperglycaemia were evaluated and compared over a period of one year.Results: Both risperidone and olanzapine were associated with comparable baseline to endpoint increase in metabolic side effects. However, risperidone treated subjects had significantly less metabolic side effects compared to olanzapine.Conclusions: Apart from total cholesterol and triglycerides, other metabolic side effects were less in risperidone treated patients than olanzapine treated patients.

scholarly journals Topical Diltiazem Versus Topical Glyceryl Trinitrate In The Management Of Chronic Anal Fissure

JMS SKIMS ◽  
2014 ◽  
Vol 17 (2) ◽  
pp. 55-58
Author(s):  
Shams Ul Bari ◽  
Ajaz Ahmad Malik ◽  
Khurshid Alam Wani ◽  
Ajaz A Rather
Keyword(s):  
Side Effects ◽  
Anal Fissure ◽  
Chronic Anal Fissure ◽  
P Value ◽  
Double Blind ◽  
Surgical Methods ◽  
Significant Difference ◽  
Topical Glyceryl Trinitrate ◽  
One Year

Background: Chemical sphincterotomy is a novel way for treating patients of chronic anal fissure which avoids the risk of fecal incontinence associated with traditional surgical methods. Aims and objectives: The aim of this study was to compare the results of topical Diltiazem with topical Glyceril trinitrate in the management of chronic anal fissure. Methods: 71 patients in the age group of 15 - 61 years with chronic anal fissure were included in this prospective, randomized, double-blind trial over a period of two years with further follow up for one year. The patients were randomly allocated to either Diltiazem gel 2% (37 patients) or Glyceril trinitrate ointment 0.2% (34 patients) and were asked to use the treatment twice daily for 8 weeks. Each patient was reviewed every two weeks. Symptoms, healing, side effects and recurrence were compared using SPSS version 10 employing X2 test. A p-value below 0.05 was considered statistically significant. Results: Patients who received topical diltiazem (DTZ) showed statistically significant difference than those who were prescribed topical glyceril trinitrate in terms of symptoms, wound healing, side effects ( headaches) and recurrence (p=0.03 and 0.003 respectively). Healing occurred in 34 of 37 (92%) patients treated with Diltiazem after 6 weeks and 27 of 34 (80%) patients treated with Glyceril trinitrate after 8 weeks, which shows a significant difference in favour of Diltiazem (P < 0.001). The rest of the patients did not heal and underwent sphincterotomy (SILS). Headache occurred in all of the patients treated with Glyceril trinitrate but none of the patients treated with Diltiazem. Conclusion: Diltiazem gel was found to be better than Glyceril trinitrate ointment due to significantly higher healing rate and fewer side-effects. JMS 2014;17(2):55-58

scholarly journals Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Izabela Fulone ◽  
Marcus Tolentino Silva ◽  
Luciane Cruz Lopes
Keyword(s):  
Gender Differences ◽  
Early Onset ◽  
Atypical Antipsychotics ◽  
Population Based ◽  
Cross Sectional Study ◽  
Administrative Database ◽  
Age Group ◽  
Early Onset Schizophrenia ◽  
Cross Sectional ◽  
Assistance Programme

Abstract Background The use of atypical antipsychotics for the treatment of schizophrenia and other mental disorders in populations under 18 years of age is increasing worldwide. Little is known about treatment patterns and the influence of gender differences, which may be a predictor of clinical outcomes. The aim of this study was to investigate gender differences in the use of atypical antipsychotics in patients with early-onset schizophrenia (EOS) assisted by the public health system in Brazil. Methods We conducted a cross-sectional study of outpatients with EOS aged 10 to 17 years who received at least one provision of atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine or ziprasidone) from a large Brazilian pharmaceutical assistance programme. Data were retrieved from a nationwide administrative database from 2008 to 2017. Results Of the 49,943 patients with EOS, 63.5% were males, and the mean age was 13.6 years old. The patients were using risperidone (62.5%), olanzapine (19.6%), quetiapine (12.4%), ziprasidone (3.3%) and clozapine (2.2%). We found gender differences, especially in the 13–17 year age group (65.1% for males vs. 34.9% for females, p < 0.001), in the use of risperidone (72.1% for males vs. 27.9% for females, p < 0.001) and olanzapine (66.5% for males vs. 33.5% for females, p < 0.001). Only in the 13 to 17 years age group were the prescribed doses of olanzapine (p = 0.012) and quetiapine (p = 0.041) slightly higher for males than for females. Conclusions Our findings showed gender differences among patients diagnosed with EOS and who received atypical antipsychotics. More attention should be devoted to gender differences in research and clinical practice.

Choice of Antenatal Steroids for Prevention of Complications of Prematurity: Betamethasone Versus Dexamethasone

2021 ◽  
pp. 097321792110483
Author(s):  
Tanushree Sahoo ◽  
Abhishek Somasekhara Aradhya ◽  
Kanya Mukhopadhyay
Keyword(s):  
Side Effects ◽  
Early Onset ◽  
Lower Cost ◽  
Antenatal Steroids ◽  
Term Adverse Effect ◽  
Early Onset Sepsis ◽  
Poor Neurological Outcome ◽  
Long Term Follow Up

Antenatal steroids (ANS) are proven strategies to maximize outcomes of premature neonates without any major maternal side effects. Their use results in decreased incidence of neonatal mortality and major morbidities (respiratory distress syndrome, early onset sepsis, necrotizing enterocolitis, and intraventricular hemorrhage). However, due to concerns of long-term adverse effect (early onset hypertension and poor neurological outcome), a close follow-up is required. Similarly, due to lack of long-term follow-up data and potential risk of hypoglycemia, a cautious use is recommended in late preterms and elective cesareans. There is currently no consensus regarding preferential use of one ANS over the other. The current review therefore tried to address these issues for use of ANS in Indian prospective in light of recent emerging evidence. Due to better safety profile, lesser side effects, lower cost, and easy storage, we recommend dexamethasone as a steroid of choice for antenatal prophylaxis.

Sign in / Sign up

Export Citation Format

Share Document